U.S. Markets closed

Daré Bioscience, Inc. (DARE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.5000+0.0800 (+5.63%)
At close: 4:00PM EDT
1.5000 0.00 (0.00%)
After hours: 07:48PM EDT

Daré Bioscience, Inc.

3655 Nobel Drive
Suite 260
San Diego, CA 92122
United States
858 926 7655
http://www.darebioscience.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees16

Key Executives

NameTitlePayExercisedYear Born
Ms. Sabrina Martucci JohnsonPres, CEO, Sec. & Director563.74kN/A1967
Ms. Lisa Walters-HoffertChief Financial Officer400.32kN/A1959
Mr. John A. FairChief Strategy Officer453.61kN/A1971
Mr. Mark WaltersVP of OperationsN/AN/A1955
Ms. MarDee J. Haring-LaytonVP of Accounting & Fin.N/AN/A1976
Dr. David FriendChief Scientific OfficerN/AN/AN/A
Ms. Mary JaroszGlobal Head of Regulatory AffairsN/AN/AN/A
Mr. John KatsilometesControllerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women's health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.

Corporate Governance

Daré Bioscience, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.